In eosinophilic esophagitis, budesonide orodispersible tablets maintained remission at 48 wk
- PMID: 33819066
- DOI: 10.7326/ACPJ202104200-044
In eosinophilic esophagitis, budesonide orodispersible tablets maintained remission at 48 wk
Abstract
Straumann A, Lucendo AJ, Miehlke S, et al. Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterology. 2020;159:1672-85. 32721437.
Keywords: Budesonide; Eosinophilic esophagitis; Glucocorticoids.
Comment on
-
Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis.Gastroenterology. 2020 Nov;159(5):1672-1685.e5. doi: 10.1053/j.gastro.2020.07.039. Epub 2020 Jul 25. Gastroenterology. 2020. PMID: 32721437 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources